Therapeutics
Category VIEW ALL
High-Affinity Farnesyltransferase Inhibitors for Treating Cryptococcal Infections
Technology No. 2021-099
Chimeric Fc receptor to augment antibody-based cell therapies
Technology No. 20180040
Synthetic cell line for high-yield rAAV production
Technology No. 2023-257
Small molecule inhibitors of TET enzymes for cancer therapy
Technology No. 2022-272
Antibodies for rapid mycoplasma hyopneumoniae detection
Technology No. 2020-097
Masked nanobodies for targeted cancer therapy
Technology No. 2022-246
Modified myeloid-derived suppressor cells for treating GvHD
Technology No. 20160072
A minipromoter for gene therapies
Technology No. 2023-188
Allogeneic extracellular vesicles for enhancing CD8+ T cell response in colorectal cancer
Technology No. 2023-280
Compounds that lead to degradation of cancer relevant proteins
Technology No. 2019-323
A tau antibody for detecting and treating Alzheimer's disease
Technology No. 20130020
Anti-viral phosphoramidates for treating SARS-CoV and influenza
Technology No. 2022-040
Novel small molecule inhibitor to target metabolic plasticity
Technology No. 2022-152
Zika as an oncolytic virus to treat brain tumors
Technology No. 20170095
Didehydro-nucleoside antiviral agents
Technology No. 2023-032
Stable glutathione analog for the treatment of Alzheimer’s disease
Technology No. 20110150
Inhibitors of Cell Adhesion by Nectin Peptides
Technology No. 20160280
Therapeutic target for treatment of ataxia
Technology No. 20160307
Glycoengineered mesenchymal stem cells as targeted therapeutic carriers
Technology No. 20160092
Hyperstable synthetic miniproteins as ligand scaffolds
Technology No. 2023-269
Progesterone receptor detection for breast cancer therapy
Technology No. 20170224
CDK2 inhibitors for cancer therapy and male contraception
Technology No. 2021-219
Inhibitory nucleic acid molecules targeting cyclin D1 mRNA
Technology No. 2022-145
Broadspectrum potentially therapeutic nanobodies against COVID-19
Technology No. 2023-140
Nanorings for cell-mediated drug delivery
Technology No. 2022-267
Efficient CRISPR-based gene editing for stem cells
Technology No. 2021-185
Single-cell Integration and DrUg Response PrediCtion (scIDUC)
Technology No. 2023-283
Pharmacological enhancement of CD8 T cell effector function using TEPP46
Technology No. 2022-294
First-in-class drug lead candidate (A229) for treating ocular diseases
Technology No. 2023-194
Bacterial histidine kinase inhibitors for treating Staphylococcus infections
Technology No. 2019-121
Small molecule inhibitors for treating alcoholic hepatitis
Technology No. 2022-250
InTERACCT Program: Occupational health and safety training
Technology No. 2023-191
Ovarian cancer prognostic test for predicting response to chemotherapy and bevacizumab
Technology No. 20180331
Bisubstrate inhibitors for treating SARS-CoV-2 infections
Technology No. 2022-100
Novel compounds for treatment of neurodegenerative disease and chronic pain
Technology No. 20160321
First-generation degraders for class I bromodomain-containing proteins
Technology No. 2022-132
NOD-2-active carboxamide compounds as vaccine adjuvants
Technology No. 2019-001
Lentivirus for keratinocyte immortalization and immortalized keratinocyte cell lines
Technology No. 2020-286
High-throughput screening assay for sickle cell disease drug discovery
Technology No. 2019-329
Mouse-derived FSHD muscle cell lines
Technology No. 2019-199
Generating teratoma-derived skeletal muscle stem cells
Technology No. 20160361
Small molecules with antiproliferative activity against pancreatic cancer cells
Technology No. 20160388
Steerable magneto-photonic particles for targeted delivery and collection of light
Technology No. 2023-107
Methods for Modifying Proteins and Peptides.
Technology No. 20180338
Treating trauma-induced acute blood loss
Technology No. 2017-0028, Z04048
Cell-free selection of site-specific polypeptide binders via tethering
Technology No. 20170034
Compound with selective inhibition potential against P300 and CBT
Technology No. 2021-151
Live cell assay to quantify the activity of SARS-CoV-2 main protease, Mpro
Technology No. 2021-102
Camelid single domain antibody phage display library
Technology No. 2020-220
T cell receptors for engineered T cell therapy
Technology No. 2020-202
A system for unattended delivery of cognitive neuromodulation therapy
Technology No. 2019-125
AGRP-derived melanocortin receptor ligands
Technology No. 20160310
Chimeric melanocortin receptor ligands
Technology No. 20160320
Selective melanocortin receptor ligands
Technology No. 20160305
Lateral flow assay for respiratory viruses
Technology No. 2020-309
A novel approach for bioprinting complex tissue models
Technology No. 2020-344
Novel anti-cancer agents that target the epigenetic reader protein
Technology No. 2021-055
Use of sulfanegen and its analogs for prevention and treatment for neurodegenerative disorders
Technology No. 2020-331
A method to identify cell-free biomarkers of cancers and other diseases
Technology No. 20170056
Assessing tumor behavior and response to therapy
Technology No. 20160224
Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
Technology No. 20170362
Fast and reliable neutralization antibodies assay for AAV gene therapy (2020-121)
Technology No. 2020-121
A streamlined method to isolate Fibroadipogenic progenitor cells from muscle (2020-195)
Technology No. 2020-195
Novel small molecules for chemotherapy sensitization
Technology No. 20180203
MHC Class II Molecules with Enhanced Co-receptor Affinity
Technology No. 20180109
Microinjection for Single Cell Gene Manipulation
Technology No. 20180069
Tosedostat (CHR-2797) as a Potential Analgesic
Technology No. 20180059
Real-Time Reporter and Efficient Enzymes for DNA Editing
Technology No. 20170418
Rationale Design of Inhibitors based on Crystal Structures of ssDNA Bound to APOBEC
Technology No. 20170124
Efficient release of affinity-captured cells
Technology No. 20160236
Peptide Activation of T Cells for Cancer Immunotherapy
Technology No. 20160174
Increased efficiency of CRISPR-Cas9 genome editing (Dr. Wendy Gordon)
Technology No. 20160269
Bacterial Biofilms Targeted with Microbial Drone Therapeutics (20140281, Dr. Christine Salomon)
Technology No. 20140281
Mesoporous Silica-coated Iron Oxide Nanoparticle (20140249, Dr. Christy Haynes)
Technology No. 20140249
ssDNA Amphiphile Self-Assembly Forms DNA Nanotubes (20140227, Dr. Efie Kokkoli)
Technology No. 20140227
Small RNA Amplification and Library Preparation (20140020, Dr. Subree Subramanian)
Technology No. 20140020
Mesoporous silica nanoparticles with ultra high porosity
Technology No. 20140012
Reagent for Dual Protein Labeling (20130255, Dr. Mark Distefano)
Technology No. 20130255
Nanoparticle Chemotherapy with Anticancer Prodrugs (20110152, Dr. Thomas Hoye)
Technology No. 20110152
Lysosomal Storage Disease Enzyme Delivery System (20100076)
Technology No. 20100076
Sarcoma miRNA Expression Database for Cancer Treatment
Technology No. 20090011